Provided by Tiger Trade Technology Pte. Ltd.

Merck

143.81
-1.5000-1.03%
Pre-market: 144.440.6300+0.44%07:00 EDT
Volume:7.86M
Turnover:1.13B
Market Cap:354.80B
PE:112.98
High:145.39
Open:144.71
Low:143.26
Close:145.31
52wk High:156.92
52wk Low:82.01
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.88
T/O Rate:0.32%
Dividend:3.32
Dividend Rate:2.31%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.46
PE(LYR):19.75

Loading ...

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Sep 24

TD Cowen Adjusts Merck Price Target to $155 From $137, Maintains Hold Rating

MT Newswires Live
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Celldex (CLDX) and Inventiva (IVA)

TIPRANKS
·
Sep 23

Merck & Co Inc : TD Cowen Raises Target Price to $155 from $137

THOMSON REUTERS
·
Sep 23

Wall Street Analysts Are Neutral on Top Healthcare Picks

TIPRANKS
·
Sep 23

Merck Gets FDA Label Update for WINREVAIR Based on HYPERION Trial

MT Newswires Live
·
Sep 22

Merck says FDA approves update for U.S. product label for Winrevair

TIPRANKS
·
Sep 22

U.S. FDA Approves Update to the Label for Winrevair to Include Data from the Phase 3 Hyperion Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension

Reuters
·
Sep 22

Merck Says Phase 3 Hyperion Trial Shows Winrevair Cuts PAH Clinical Worsening Risk 76%

Reuters
·
Sep 22

Nvidia Corp., Merck Share Gains Lead Dow's 425-Point Climb

Dow Jones
·
Sep 22

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 21

Japan Health Ministry Approves Merck’s Keytruda QLEX for Subcutaneous Use Across Keytruda Indications

Reuters
·
Sep 21

Merck’s Keytruda Qlex™ (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Approved in Japan for Subcutaneous Administration for All Keytruda® (Pembrolizumab) Indications Approved in Japan

THOMSON REUTERS
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 21

Merck Says EU CHMP Backs Keytruda-Padcev Perioperative Use in Resectable Muscle-Invasive Bladder Cancer

Reuters
·
Sep 18

Merck & Co - Final Ec Decision Expected by Q4 2026

THOMSON REUTERS
·
Sep 18

Merck Receives Positive EU Chmp Opinion for Keytruda® (Pembrolizumab) Plus Padcev® (Enfortumab Vedotin-Ejfv) as Perioperative Treatment for Adults with Resectable Muscle-Invasive Bladder Cancer (Mibc)

THOMSON REUTERS
·
Sep 18

Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living with Hiv

THOMSON REUTERS
·
Sep 18